Dishman Carbogen Amcis Limited (DCAL.NS)
INR 209.88
(2.91%)
INR 209.88
(2.91%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 26.15 Billion INR | 8.41% |
| 2022 | 24.12 Billion INR | 12.72% |
| 2021 | 21.4 Billion INR | 11.96% |
| 2020 | 19.12 Billion INR | -6.44% |
| 2019 | 20.43 Billion INR | -0.73% |
| 2018 | 20.58 Billion INR | 21.48% |
| 2017 | 16.94 Billion INR | -1.11% |
| 2016 | 17.13 Billion INR | 7.37% |
| 2015 | 15.96 Billion INR | 1.32% |
| 2014 | 15.75 Billion INR | 13.71% |
| 2013 | 13.85 Billion INR | 8.88% |
| 2012 | 12.72 Billion INR | 13.18% |
| 2011 | 11.24 Billion INR | 13.45% |
| 2010 | 9.9 Billion INR | 8.25% |
| 2009 | 9.15 Billion INR | -13.84% |
| 2008 | 10.62 Billion INR | 32.29% |
| 2007 | 8.03 Billion INR | 38.8% |
| 2006 | 5.78 Billion INR | 108.54% |
| 2005 | 2.77 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 5.23 Billion INR | -20.0% |
| 2023 Q2 | 5.86 Billion INR | -18.91% |
| 2023 Q1 | 7.23 Billion INR | 16.95% |
| 2023 FY | 26.15 Billion INR | 8.41% |
| 2023 Q4 | 6.54 Billion INR | 0.56% |
| 2023 Q3 | 6.51 Billion INR | 11.0% |
| 2022 FY | 24.12 Billion INR | 12.72% |
| 2022 Q1 | 5.4 Billion INR | -4.99% |
| 2022 Q2 | 6.13 Billion INR | 13.57% |
| 2022 Q4 | 6.18 Billion INR | -3.32% |
| 2022 Q3 | 6.39 Billion INR | 4.21% |
| 2021 Q4 | 5.68 Billion INR | 1.23% |
| 2021 FY | 21.4 Billion INR | 11.96% |
| 2021 Q2 | 4.58 Billion INR | -16.67% |
| 2021 Q1 | 5.5 Billion INR | 3.28% |
| 2021 Q3 | 5.62 Billion INR | 22.48% |
| 2020 FY | 19.12 Billion INR | -6.44% |
| 2020 Q4 | 5.33 Billion INR | 15.11% |
| 2020 Q3 | 4.63 Billion INR | 5.18% |
| 2020 Q2 | 4.4 Billion INR | -7.31% |
| 2020 Q1 | 4.75 Billion INR | -17.1% |
| 2019 Q1 | 5.01 Billion INR | -33.17% |
| 2019 FY | 20.43 Billion INR | -0.73% |
| 2019 Q2 | 4.49 Billion INR | -10.27% |
| 2019 Q4 | 5.73 Billion INR | 10.36% |
| 2019 Q3 | 5.19 Billion INR | 15.47% |
| 2018 Q3 | 4.27 Billion INR | -1.16% |
| 2018 Q2 | 4.32 Billion INR | -3.64% |
| 2018 Q1 | 4.48 Billion INR | -0.84% |
| 2018 Q4 | 7.5 Billion INR | 75.5% |
| 2018 FY | 20.58 Billion INR | 21.48% |
| 2017 Q4 | 4.52 Billion INR | 5.02% |
| 2017 FY | 16.94 Billion INR | -1.11% |
| 2017 Q3 | 4.3 Billion INR | 0.03% |
| 2017 Q2 | 4.3 Billion INR | 27.83% |
| 2017 Q1 | 3.36 Billion INR | -30.82% |
| 2016 Q1 | 3.65 Billion INR | 2.64% |
| 2016 Q2 | 4.26 Billion INR | 16.69% |
| 2016 Q4 | 4.87 Billion INR | 36.65% |
| 2016 Q3 | 3.56 Billion INR | -16.51% |
| 2016 FY | 17.13 Billion INR | 7.37% |
| 2015 Q3 | 3.82 Billion INR | 2.36% |
| 2015 Q4 | 3.56 Billion INR | -6.8% |
| 2015 FY | 15.96 Billion INR | 1.32% |
| 2015 Q1 | 4 Billion INR | -8.14% |
| 2015 Q2 | 3.73 Billion INR | -6.59% |
| 2014 Q4 | 4.35 Billion INR | 12.86% |
| 2014 Q3 | 3.85 Billion INR | -1.65% |
| 2014 Q1 | 3.61 Billion INR | -12.38% |
| 2014 Q2 | 3.92 Billion INR | 8.51% |
| 2014 FY | 15.75 Billion INR | 13.71% |
| 2013 Q4 | 4.12 Billion INR | 31.66% |
| 2013 Q3 | 3.13 Billion INR | -11.19% |
| 2013 Q2 | 3.52 Billion INR | 15.24% |
| 2013 Q1 | 3.06 Billion INR | -12.53% |
| 2013 FY | 13.85 Billion INR | 8.88% |
| 2012 Q3 | 3.17 Billion INR | 9.79% |
| 2012 Q4 | 3.5 Billion INR | 10.24% |
| 2012 Q1 | 3.15 Billion INR | -10.61% |
| 2012 FY | 12.72 Billion INR | 13.18% |
| 2012 Q2 | 2.89 Billion INR | -8.25% |
| 2011 Q4 | 3.52 Billion INR | 32.9% |
| 2011 Q3 | 2.65 Billion INR | 0.0% |
| 2011 FY | 11.24 Billion INR | 13.45% |
| 2010 FY | 9.9 Billion INR | 8.25% |
| 2009 FY | 9.15 Billion INR | -13.84% |
| 2008 FY | 10.62 Billion INR | 32.29% |
| 2007 FY | 8.03 Billion INR | 38.8% |
| 2006 FY | 5.78 Billion INR | 108.54% |
| 2005 FY | 2.77 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Biocon Limited | 147.55 Billion INR | 82.273% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | -267.591% |
| Concord Biotech Limited | 9.98 Billion INR | -162.086% |
| Jubilant Ingrevia Limited | 41 Billion INR | 36.208% |
| Lyka Labs Limited | 1.05 Billion INR | -2388.075% |
| Panacea Biotec Limited | 5.59 Billion INR | -367.795% |
| Piramal Pharma Limited | 81.71 Billion INR | 67.988% |
| SMS Lifesciences India Limited | 3.05 Billion INR | -754.943% |
| Supriya Lifescience Limited | 5.7 Billion INR | -358.609% |
| Syngene International Limited | 34.88 Billion INR | 25.019% |
| TAKE Solutions Limited | 656.08 Million INR | -3886.968% |
| Zota Health Care Limited | 1.8 Billion INR | -1349.272% |